Name: An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes (Video) | JoVE Journal
Uploaded: 2019-04-26T14:30:00.000+00:00
Duration: 10 min 17 s
Description: Learn to isolate adipose and hepatic immune cells from mice with diet-induced nonalcoholic steatohepatitis using non-SPF housing and flow cytometry. This method advances immunometabolism research.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

We thank Anke Jurisch, Diana Woellner, Dr. Kathrin Witte and Cornelia Heckmann for assistance with experimental procedures and Benjamin Tiburzy from Biolegend for helpful comments on the gating strategy. J.S. was supported by the Helmholtz Grant (ICEMED). This study was supported by grants from the Clinical Research Unit of the Berlin Institute of Health (BIH), the &#8220;BCRT-grant&#8221; by the German Federal Ministry of Education and Research and the Einstein Foundation. K.S.-B. and H.-D.V. are funded by FOR2165.

This study was carried out in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the Animal Welfare Act under the supervision of our institutional Animal Care and Use Committee. Animal protocols were conducted according to institutional ethical guidelines of the Charit&#233; Berlin, Germany, and were approved by the Landesamt f&#252;r Gesundheit und Soziales and comply with the ARRIVE guidelines.
1. Diet-induced Animal Model of Steatohepatitis
<ol>
	<li>Transfer mice (C57Bl/6J, male) to non-SPF housing at the age of 4 weeks and expose them continuously to a broad range of environmental pathogens/antigens. Guarantee the exposure by daily handling of the laboratory animals as antigens are distributed by air passage in this way.</li>
	<li>Maintain mice (C57Bl/6J, male, 12 weeks old) in open caging systems with conventional filters on a 12 h:12 h light/dark cycle at a temperature of 22 &#176;C. Do not irradiate or autoclave experimental diet and bedding. Access animal housing facility without mask or hairnet. Open doors between animal rooms. Do not use an airshower.</li>
	<li>Guarantee daily handling of the laboratory animals and switch rooms on a regular basis so that antigens are distributed by air passage. Complement dirty housing with daily non-specific microbial exposure to antigens from bedding of mammalian laboratory animals housed in rooms next to the laboratory mice.</li>
	<li>Measure proportions of CD44-CD62L- effector memory CD4+ and CD8+ T cells in blood and spleen using flow cytometry (as described in refefence13). 
	NOTE: In this regard we defined an increase of 20% of effector memory CD8+ T cells from CD8+ T cells as evidence of sufficient microbial exposure.</li>
	<li>Start HFD (60 kJ% from fat, 19 kJ% from proteins and 21 kJ% from carbohydrates and ad libitum consumption of water with 6% sucrose content with five-week old C57Bl/6J male mice for 7-15 weeks. The HFD should contain 60% kJ from fat (as described above) in order to induce the development of insulin resistance throughout the course of the experiment. 
	NOTE: Hematoxylin staining should be performed and histological characteristics as hepatocyte ballooning, Mallory Denk bodies, immune cell infiltration and macrovesicular steatosis must be found to demonstrate NASH-like liver pathology (as shown in reference13).</li>
</ol>
2. Preparation of Reagents and Solutions
<ol>
	<li>Prepare 70% ethanol, phosphate buffered saline (PBS, without calcium and magnesium) supplemented with 0.5% BSA and ACK (Ammonium-Chloride-Potassium) lysis buffer.</li>
	<li>Staining buffer
	<ol>
		<li>Dissolve 10 mL of fetal calf serum (FCS) in 500 mL of PBS to obtain 2% FCS PBS. Place staining buffer on ice before use.</li>
		<li>Store solution in a plastic bottle at 4 &#176;C.</li>
	</ol>
	</li>
	<li>Collagenase solution for adipose tissue digestion
	<ol>
		<li>Dissolve 2.5 g of bovine serum albumin (BSA) in 500 mL of PBS to obtain a 0.5% BSA/PBS.</li>
		<li>Dissolve 74.5 g of CaCl2 in 10 mL of 0.5% BSA/PBS to obtain a 10 mM CaCl2 solution.</li>
		<li>Add 1 mg of collagenase type II (see Table of Materials) to each mL of 0.5% BSA with 10 mM CaCl2 PBS.</li>
		<li>Prepare 3 mL of collagenase digest solution per g of adipose tissue sample. Prepare fresh collagenase solution for each isolation.</li>
	</ol>
	</li>
	<li>Collagenase solution for liver tissue digestion
	<ol>
		<li>Dissolve 2.5 g of BSA in 500 mL of Hank&#180;s Balanced Salt Solution (HBSS) to obtain 0.5% BSA HBSS.</li>
		<li>Add 10 mL of FCS in 500 mL of 0.5% BSA/HBSS to obtain 2% FCS 0.5% BSA/HBSS.</li>
		<li>Add 0.5 mg of collagenase type IV (see Table of Materials) to each mL of 2% FCS 0.5% BSA/HBSS.</li>
		<li>Add 0.02 mg of DNase per mL of 2% FCS 0.5% BSA/HBSS collagenase solution.</li>
		<li>Prepare 13 mL of collagenase digest solution per liver tissue sample.</li>
		<li>Prepare fresh collagenase solution for each isolation.</li>
	</ol>
	</li>
</ol>
3. Generation of Single cell Suspensions
<ol>
	<li>Adipose tissue digestion
	<ol>
		<li>Euthanize mice via isoflurane anesthesia followed by cervical dislocation. Spray the chest with 70% ethanol. Carefully make a 5-6 cm central incision through the integument and abdominal wall along the entire length of the rib cage to expose the pleural cavity and heart. 
		NOTE: Do not damage underlying organs and keep scissors tips up.</li>
		<li>Inject at least 10 mL of 0.9% saline solution in the apex of the left ventricle using a 26 G needle. 
		NOTE: Successful perfusion is noted by blanching of the liver.</li>
		<li>Open the peritoneal cavity with scissors and cut out the perigonadal fat pads on each side with fine curved scissors. Dissect gonadal tissues with fine curved scissors and weigh adipose tissue.</li>
		<li>Perform the mechanical dissociation using scissors and cut adipose tissue into fine pieces in a Petri dish at 4 &#176;C. Transfer adipose tissue to 50 mL conical centrifuge tubes and rinse Petri dish with 1 mL of 0.5% BSA/PBS.</li>
		<li>Add 3 mL of adipose tissue digest solution (as prepared in step 2.3) per gram of adipose tissue. Incubate adipose tissue solution at 37 &#176;C for 20 min under gentle shaking (200 rpm).</li>
		<li>Add 5 mL of 0.5% BSA/PBS per gram of adipose tissue and place on ice. Triturate the solution numerous times with a 10 mL serological pipette and pass it through a strainer (100 &#181;m) with the aid of a plunger.</li>
		<li>Centrifuge at 500 x g for 10 min at 4 &#176;C.</li>
		<li>Remove the floating adipocyte fraction by pipetting. Resuspend the cell pellet (stromal vascular fraction) in 1 mL of ACK lysis buffer (see Table of Materials). Add 10 mL of 2% FCS PBS.</li>
		<li>Centrifuge at 500 x g for 10 min at 4 &#176;C.</li>
		<li>Decant supernatant and resuspend cell pellet in 250 &#181;L of 2% FCS PBS.</li>
		<li>Count the number of viable cells on a hemocytometer using Trypan blue exclusion.</li>
	</ol>
	</li>
	<li>Liver tissue digestion
	<ol>
		<li>Store liver in a conical centrifuge tube filled with PBS and transport on ice.</li>
		<li>Perform the mechanical dissociation using syringe stamps in a Petri dish at 4 &#176;C. Put dissected liver tissue in a 50 mL conical centrifuge tube containing 10 mL of warm liver digest solution. Rinse the Petri dish with 3 mL of liver digest solution.</li>
		<li>Incubate liver tissue solution at 37 &#176;C for 20 min under gentle shaking (200 rpm).</li>
		<li>Add 20 mL of HBSS. Triturate the solution numerous times with a 10 mL serological pipette and pass it through a strainer (100 &#181;m) with the aid of a plunger.</li>
		<li>Centrifuge at 500 x g for 10 min at 4 &#176;C. Decant the supernatant and resuspend the cell pellet in 20 mL of HBSS.</li>
		<li>Centrifuge at 30 x g for 1 min at room temperature to remove the hepatocyte matrix. Discard the cell pellet.</li>
		<li>Centrifuge the supernatant at 500 x g for 10 min at 4 &#176;C. Resuspend the pellet in 10 mL of 33% low viscosity density gradient medium solution (see Table of Materials) in HBSS followed by centrifugation (800 x g; 30 min; room temperature; no brake).</li>
		<li>Resuspend the pellet in 1 mL of ACK lysis buffer and incubate for 4 min at room temperature. Then add 10 mL of HBSS. 
		NOTE: To discard the supernatant aspirate the supernatant with interphase (hepatocytes) very carefully with a transfer pipette (as much as possible without taking the pellet with immune cells and erythrocytes).</li>
		<li>Pass cells through a 30 &#956;m strainer in a 15 mL conical centrifuge tube and centrifuge at 500 x g for 10 min at 4 &#176;C. Decant supernatant and resuspend cell pellet in 250 &#181;L of 2% FCS PBS.</li>
		<li>Count the number of viable cells on a hemocytometer using Trypan blue exclusion.</li>
	</ol>
	</li>
</ol>
4. Surface Staining
<ol>
	<li>Prepare antibody mix for T-cell-subsets (Panel 1) and innate immune cells (Panel 2) as described in Table 1 and Table 2. Volumes are optimized for one sample (100 &#181;L) regarding to antibody concentrations. 
	NOTE: Lymphocytes and innate immune cells present differences in autofluorescence and should be analyzed separately.</li>
	<li>Use up to 3 x 106 cells in 100 &#181;L in a polystyrene FACS tube for surface staining. To block Fc receptors add 10 &#181;L of anti-CD16/CD32 antibody (diluted 1:100) and incubate for 10 min on ice. Use an unstained negative control sample to adjust side scatter (SSC) and forward scatter (FSC) to determine the location of the negative cell population.</li>
	<li>Vortex and add the appropriate volume of antibody mixture for Panel 1 and Panel 2. Add 1 &#181;L of viability dye to each sample to allow for live and dead cell discrimination. Incubate for 20 min at 4 &#176;C and protected from light.</li>
	<li>Wash two times with 2 mL of 2% FCS PBS and centrifuge at 300 x g for 5 min at 4 &#176;C.</li>
	<li>Resuspend the cell pellet in 300 &#181;L of 2% FCS PBS and store at 4 &#176;C until FACS analysis. 
	NOTE: Before starting the measurement pass cells through 30 &#181;m cell strainer into polystyrene FACS tube and vortex. Flow cytometry was performed with labeled cells stored in 2% FCS PBS at 4 &#176;C for 1-3 h. Cells should be analyzed as soon as possible for optimized results.</li>
</ol>
5. Flow Cytometry Compensation, Acquisition, and Gating
<ol>
	<li>Run unstained negative control sample to set the FSC and SSC and adjust voltages of the flow cytometer to detect leucocyte populations and to distinguish between debris and viable cells. Exclude debris and dead cells. 
	NOTE: Viability of the cell suspensions from the liver might be lower than the viability from the cell suspensions from perigonadal adipose tissue due to an additional density separation step.</li>
	<li>Run single stained control samples for multi-color compensation. 
	NOTE: Antibody capture beads could also be used to adjust for spectral overlap if the number of cells of a cell population of interest is too low to compensate using cells. To detect possible autofluorescence signals of the cells fluorescence minus one (FMO) controls for every antibody are recommended but were not applied in this protocol.</li>
	<li>Start the measurement, collect appropriate number of events (at least 50,000 events) and record experimental data.</li>
	<li>Export FCS data files for analysis and set the gating strategy. Gate on CD45+ leucocytes to identify subsequent cell populations.</li>
</ol>

<ol><li>Guh, D. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+incidence+of+co-morbidities+related+to+obesity+and+overweight%3A+A+systematic+review+and+meta-analysis%5BTitle%5D)+AND+%22BMC+Public+Health%22%5BJournal%5D)">The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis.</a> BMC Public Health. 9, 88(2009).</li>
<li>Prentki, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Islet+%CE%B2+cell+failure+in+type%5BTitle%5D)+AND+%22J+Clin+Invest%22%5BJournal%5D)">Islet β cell failure in type.</a> J Clin Invest. 116 (7), 1802-1812 (2006).</li>
<li>Shoelson, S. E., Lee, J., Goldfine, A. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Inflammation+and+insulin+resistance%5BTitle%5D)+AND+%22Journal+of+Clinical+Investigation%22%5BJournal%5D)">Inflammation and insulin resistance.</a> Journal of Clinical Investigation. 116 (7), 1793-1801 (2006).</li>
<li>Kahn, S. E., Hull, R. L., Utzschneider, K. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mechanisms+linking+obesity+to+insulin+resistance+and+type+2+diabetes%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Mechanisms linking obesity to insulin resistance and type 2 diabetes.</a> Nature. 444, 840(2006).</li>
<li>Exley, M. A., Hand, L., O'Shea, D., Lynch, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Interplay+between+the+immune+system+and+adipose+tissue+in+obesity%5BTitle%5D)+AND+%22Journal+of+Endocrinology%22%5BJournal%5D)">Interplay between the immune system and adipose tissue in obesity.</a> Journal of Endocrinology. 223 (2), R41-R48 (2014).</li>
<li>Ferrante, A. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Macrophages%2C+fat%2C+and+the+emergence+of+immunometabolism%5BTitle%5D)+AND+%22Journal+of+Clinical+Investigation%22%5BJournal%5D)">Macrophages, fat, and the emergence of immunometabolism.</a> Journal of Clinical Investigation. 123 (12), 4992-4993 (2013).</li>
<li>Winer, D. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((B+cells+promote+insulin+resistance+through+modulation+of+T+cells+and+production+of+pathogenic+IgG+antibodies%5BTitle%5D)+AND+%22Nature+Medicine%22%5BJournal%5D)">B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies.</a> Nature Medicine. 17, 610(2011).</li>
<li>Onodera, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Adipose+tissue+macrophages+induce+PPAR%CE%B3-high+FOXP3%28%2B%29+regulatory+T+cells%5BTitle%5D)+AND+%22Scientific+Reports%22%5BJournal%5D)">Adipose tissue macrophages induce PPARγ-high FOXP3(+) regulatory T cells.</a> Scientific Reports. 5, (2015).</li>
<li>Lackey, D. E., Olefsky, J. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Regulation+of+metabolism+by+the+innate+immune+system%5BTitle%5D)+AND+%22Nature+Reviews+Endocrinology%22%5BJournal%5D)">Regulation of metabolism by the innate immune system.</a> Nature Reviews Endocrinology. 12, 15(2015).</li>
<li>Calle, E. E., Kaaks, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Overweight%2C+obesity+and+cancer%3A+epidemiological+evidence+and+proposed+mechanisms%5BTitle%5D)+AND+%22Nature+Reviews+Cancer%22%5BJournal%5D)">Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms.</a> Nature Reviews Cancer. 4, 579(2004).</li>
<li>Ibrahim, S. H., Hirsova, P., Malhi, H., Gores, G. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Animal+Models+of+Nonalcoholic+Steatohepatitis%3A+Eat%2C+Delete%2C+and+Inflame%5BTitle%5D)+AND+%22Digestive+Diseases+and+Sciences%22%5BJournal%5D)">Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame.</a> Digestive Diseases and Sciences. 61 (5), 1325-1336 (2016).</li>
<li>Beura, L. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Recapitulating+adult+human+immune+traits+in+laboratory+mice+by+normalizing+environment%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Recapitulating adult human immune traits in laboratory mice by normalizing environment.</a> Nature. 532 (7600), 512-516 (2016).</li>
<li>Sbierski-Kind, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Distinct+Housing+Conditions+Reveal+a+Major+Impact+of+Adaptive+Immunity+on+the+Course+of+Obesity-Induced+Type+2+Diabetes%5BTitle%5D)+AND+%22Frontiers+in+Immunology%22%5BJournal%5D)">Distinct Housing Conditions Reveal a Major Impact of Adaptive Immunity on the Course of Obesity-Induced Type 2 Diabetes.</a> Frontiers in Immunology. 9 (1069), (2018).</li>
<li>Japp, A. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Wild+immunology+assessed+by+multidimensional+mass+cytometry%5BTitle%5D)+AND+%22Cytometry+Part+A%22%5BJournal%5D)">Wild immunology assessed by multidimensional mass cytometry.</a> Cytometry Part A. 91 (1), 85-95 (2017).</li>
<li>Benedict, M., Zhang, X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Non-alcoholic+fatty+liver+disease%3A+An+expanded+review%5BTitle%5D)+AND+%22World+Journal+of+Hepatology%22%5BJournal%5D)">Non-alcoholic fatty liver disease: An expanded review.</a> World Journal of Hepatology. 9 (16), 715-732 (2017).</li>
<li>McNelis, J. C., Olefsky, J. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Macrophages%2C+Immunity%2C+and+Metabolic+Disease%5BTitle%5D)+AND+%22Immunity%22%5BJournal%5D)">Macrophages, Immunity, and Metabolic Disease.</a> Immunity. 41 (1), 36-48 (2014).</li>
<li>Ferrante, A. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+Immune+Cells+in+Adipose+Tissue%5BTitle%5D)+AND+%22Diabetes%2C+Obesity+%26+Metabolism%22%5BJournal%5D)">The Immune Cells in Adipose Tissue.</a> Diabetes, Obesity & Metabolism. 15, 34-38 (2013).</li>
<li>Bertola, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hepatic+expression+patterns+of+inflammatory+and+immune+response+genes+associated+with+obesity+and+NASH+in+morbidly+obese+patients%5BTitle%5D)+AND+%22PloS+One%22%5BJournal%5D)">Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients.</a> PloS One. 5 (10), e13577(2010).</li>
<li>Turnbaugh, P. J., Bäckhed, F., Fulton, L., Gordon, J. I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Diet-Induced+Obesity+Is+Linked+to+Marked+but+Reversible+Alterations+in+the+Mouse+Distal+Gut+Microbiome%5BTitle%5D)+AND+%22Cell+Host+%26+Microbe%22%5BJournal%5D)">Diet-Induced Obesity Is Linked to Marked but Reversible Alterations in the Mouse Distal Gut Microbiome.</a> Cell Host & Microbe. 3 (4), 213-223 (2008).</li>
<li>Singh, R. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Influence+of+diet+on+the+gut+microbiome+and+implications+for+human+health%5BTitle%5D)+AND+%22Journal+of+Translational+Medicine%22%5BJournal%5D)">Influence of diet on the gut microbiome and implications for human health.</a> Journal of Translational Medicine. 15 (1), 73(2017).</li>
<li>Müller, V. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Gut+barrier+impairment+by+high-fat+diet+in+mice+depends+on+housing+conditions%5BTitle%5D)+AND+%22Molecular+Nutrition+%26+Food+Research%22%5BJournal%5D)">Gut barrier impairment by high-fat diet in mice depends on housing conditions.</a> Molecular Nutrition & Food Research. 60 (4), 897-908 (2016).</li>
</ol>

The authors have nothing to disclose.

Steatohepatitis has a strong association with metabolic abnormalities such as obesity, insulin resistance and dyslipidemia15. Multiple studies indicate that adipose tissue inflammation can drive the pathogenesis of type 2 diabetes, including altered levels of cells of both the innate and adaptive immune system4,5,16,17. In addition, it has been found that obesity modulat...

Obesity is a multifactorial disorder and a major risk factor for developing heart disease, stroke, nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D) and some types of cancer. The prevalence of obesity is rapidly increasing globally. Today, 2.1 billion people &#8212;&#160;nearly 30% of the world&#8217;s population &#8212; are either obese or overweight1. Obesity-associated insulin resistance can lead to T2D, when exhausted pancreatic islet beta cells fail to compensate for the increased need for insulin to maintain glucose homeostasis2.
Adipose tissue is composed of various cell types including adipocytes, endothelial cells, fibroblasts and immune cells. During progression of obesity, changes in the number and activity of immune cells can lead to low-grade inflammation of hypertrophic adipose tissue3,4. Specifically, it has been found that excessive energy intake, accompanied by chronically elevated levels of blood glucose, triglycerides and free fatty acids, leads to adipocyte hypoxia, endoplasmic reticulum stress, impaired mitochondrial function and enhanced cytokine secretion, resulting in the activation of pro-inflammatory adipose immune cells5,6. Past research has mainly focused on innate immunity, but more recently adaptive immune cells (T and B cells) have emerged as important regulators of glucose homeostasis. They possess inflammatory (including CD8+ T cells, Th1, and B cells) or primarily regulatory functions (including regulatory T (Treg) cells, Th2 cells) and can both exacerbate or protect against insulin resistance7,8,9.
Furthermore, several mechanisms were proposed to explain how obesity increases steatohepatitis, including increased production of cytokines by adipose tissue10. NASH, the progressive form of nonalcoholic fatty liver disease and a major health burden in developed countries, is histologically characterized by ballooned hepatocytes, lipid accumulation, fibrosis and pericellular inflammation and may progress to cirrhosis, end stage liver disease or hepatocellular carcinoma. Several regimen (for instance the methionine and choline deficient diet11) are known to induce NASH-like liver pathology in non-human animal models, but most of these approaches do not recapitulate human conditions of NASH and its metabolic consequences as they either require specific gene knockout, non-physiological dietary manipulations or lack insulin resistance typical of human NASH. Moreover, our understanding of the underlying mechanisms of metabolic diseases is currently based on experiments carried out with laboratory mice housed under standard specific pathogen free (SPF) conditions. Those barrier facilities are abnormally hygienic and do not consider the microbial diversity humans have to encounter, which may account for difficulties in the translation process of animal studies to clinical approaches12,13,14.
To investigate the different immune cell subsets in adipose tissue and liver during the development of insulin resistance and NASH in an advanced mouse model reproducing human immunological conditions, mice were housed in individual cages in semi sterile conditions without a barrier. Mice housed under antigen exposed conditions developed NASH-like liver pathology already after 15 weeks of high-fat diet (HFD) feeding13. Compared to age-matched SPF mice they developed macrovesicular steatosis, hepatic infiltration and activation of immune cells.
This manuscript describes a robust flow cytometry analysis to define and count immune cell subsets from mouse adipose tissue and liver in a model of NASH. Flow cytometry analysis allows the detection of multiple parameters of individual cells simultaneously in contrast to RT-PCR or immunohistochemistry approaches.
In summary, our study offers a mouse model of short-term HFD for investigating the development of insulin resistance and NASH and the underlying mechanisms that also exhibits fidelity to the human condition.

<table><tbody><tr><td>100 &amp;micro;m cell strainers&amp;nbsp;</td><td>Falcon</td><td>352340</td><td></td></tr><tr><td>1 mL syringe&amp;nbsp;</td><td>BD&amp;nbsp;&amp;nbsp;</td><td>309659</td><td></td></tr><tr><td>26 G x 5/8 needles&amp;nbsp;</td><td>BD&amp;nbsp;</td><td>305115</td><td></td></tr><tr><td>35 mm Petri Dishes&amp;nbsp;</td><td>Falcon</td><td>353001</td><td></td></tr><tr><td>40 &amp;micro;m cell strainers&amp;nbsp;</td><td>Falcon</td><td>352340</td><td></td></tr><tr><td>ACK lysis buffer&amp;nbsp;</td><td>GIBCO</td><td>A1049201</td><td></td></tr><tr><td>Alexa Fluor 700 anti-mouse CD45</td><td>Biolegend&amp;nbsp;</td><td>103127</td><td>AB_493714 (BioLegend Cat. No. 103127)</td></tr><tr><td>Analysis software&amp;nbsp;</td><td>FlowJo 10.0.8 software</td><td></td><td></td></tr><tr><td>APC anti-mouse CD11c Antibody</td><td>Biolegend&amp;nbsp;</td><td>117309</td><td>AB_313778 (BioLegend Cat. No. 117309)</td></tr><tr><td>APC anti-mouse KLRG1 (MAFA) Antibody</td><td>Biolegend&amp;nbsp;</td><td>138411</td><td>AB_10645509 (BioLegend Cat. No. 138411)</td></tr><tr><td>BV421 anti-mouse CD127 Antibody</td><td>Biolegend&amp;nbsp;</td><td>135023</td><td>AB_10897948 (BioLegend Cat. No. 135023)</td></tr><tr><td>BV421 anti-mouse F4/80 Antibody</td><td>Biolegend&amp;nbsp;</td><td>123131</td><td>AB_10901171 (BioLegend Cat. No. 123131)</td></tr><tr><td>BV605 anti-mouse CD279 (PD-1) Antibody</td><td>Biolegend&amp;nbsp;</td><td>135219</td><td>AB_11125371 (BioLegend Cat. No. 135219)</td></tr><tr><td>BV605 anti-mouse NK-1.1 Antibody</td><td>Biolegend&amp;nbsp;</td><td>108739</td><td>AB_2562273 (BioLegend Cat. No. 108739)</td></tr><tr><td>BV650 anti-mouse/human CD11b Antibody</td><td>Biolegend&amp;nbsp;</td><td>101239</td><td>AB_11125575 (BioLegend Cat. No. 101239)</td></tr><tr><td>BV711 anti-mouse/human B220 Antibody</td><td>Biolegend&amp;nbsp;</td><td>103255</td><td>AB_2563491 (BioLegend Cat. No. 103255)</td></tr><tr><td>BV785 anti-mouse CD8a Antibody</td><td>Biolegend&amp;nbsp;</td><td>100749</td><td>AB_11218801 (BioLegend Cat. No. 100749)</td></tr><tr><td>C57Bl/6J mice, male, 5 weeks old&amp;nbsp;</td><td>Forschungseinrichtungen f&amp;uuml;r experimentelle Medizin (FEM)</td><td></td><td></td></tr><tr><td>CaCl&lt;sub&gt;2&lt;/sub&gt;&amp;nbsp;</td><td>Charit&amp;eacute; - Universit&amp;auml;tsmedizin Berlin</td><td>A119.1&amp;nbsp;</td><td></td></tr><tr><td>Collagenase NB 4G Proved Grade&amp;nbsp;</td><td>SERVA&amp;nbsp;</td><td>11427513</td><td></td></tr><tr><td>Collagenase Typ I&amp;nbsp;</td><td>Worthington&amp;nbsp;</td><td>LS004197</td><td></td></tr><tr><td>Conical centrifuge tube 15mL&amp;nbsp;</td><td>Falcon</td><td>352096</td><td></td></tr><tr><td>Conical centrifuge tube 50 mL&amp;nbsp;</td><td>Falcon</td><td>352070</td><td></td></tr><tr><td>DNAse&amp;nbsp;&amp;nbsp;</td><td>Sigma-Aldrich&amp;nbsp;</td><td>4716728001</td><td></td></tr><tr><td>Fetal bovine serum&amp;nbsp;</td><td>Biochrom</td><td>S0115</td><td></td></tr><tr><td>Filter 30&amp;micro;m&amp;nbsp;</td><td>Celltrics&amp;nbsp;</td><td>400422316</td><td></td></tr><tr><td>FITC anti-mouse CD3 Antibody</td><td>Biolegend&amp;nbsp;</td><td>100203</td><td>AB_312660 (BioLegend Cat. No. 100203)</td></tr><tr><td>Flow cytometry&amp;nbsp;</td><td>BD-LSR Fortessa&amp;nbsp;</td><td></td><td></td></tr><tr><td>Forceps&amp;nbsp;</td><td>Sigma-Aldrich&amp;nbsp;</td><td>F4142-1EA</td><td></td></tr><tr><td>HBSS&amp;nbsp;</td><td>Bioanalytic GmBH&amp;nbsp;</td><td>085021-0500&amp;nbsp;</td><td></td></tr><tr><td>High-fat diet&amp;nbsp;</td><td>SSNIF</td><td>E15741&amp;ndash;34&amp;nbsp;</td><td>60 kJ% from fat, 19&amp;thinsp;kJ% from proteins, and 21&amp;thinsp;kJ% from carbohydrates</td></tr><tr><td>micro dissecting scissors&amp;nbsp;</td><td>Sigma-Aldrich&amp;nbsp;</td><td>S3146</td><td>used for dissection purposes&amp;nbsp;</td></tr><tr><td>PE anti-mouse CD25 Antibody</td><td>Biolegend&amp;nbsp;</td><td>101903</td><td>AB_312846 (BioLegend Cat. No. 101903)</td></tr><tr><td>PE/Cy7 anti-mouse CD62L Antibody</td><td>Biolegend&amp;nbsp;</td><td>104417</td><td>AB_313102 (BioLegend Cat. No. 104417)</td></tr><tr><td>PE/Cy7 anti-mouse I-A/I-E (MHCII) Antibody</td><td>Biolegend&amp;nbsp;</td><td>107629</td><td>AB_2290801 (BioLegend Cat. No. 107629)</td></tr><tr><td>PE/Dazzle 594 anti-mouse CD4 Antibody</td><td>Biolegend&amp;nbsp;</td><td>100565</td><td>AB_2563684 (BioLegend Cat. No. 100565)</td></tr><tr><td>Percoll solution&amp;nbsp;</td><td>Biochrom</td><td>L6115</td><td></td></tr><tr><td>PerCP/Cy5.5 anti-mouse CD44 Antibody</td><td>Biolegend&amp;nbsp;</td><td>103031</td><td>AB_2076206 (BioLegend Cat. No. 103031)</td></tr><tr><td>PerCP/Cy5.5 anti-mouse Gr-1 Antibody</td><td>Biolegend&amp;nbsp;</td><td>108427</td><td>AB_893561 (BioLegend Cat. No. 108427)</td></tr><tr><td>Phosphate buffered saline&amp;nbsp;</td><td>Gibco</td><td>12559069</td><td></td></tr><tr><td>Round-Bottom Tubes with cell strainer cap</td><td>STEMCELL Technologies&amp;nbsp;</td><td>38030</td><td></td></tr><tr><td>TruStain fcX anti-mouse CD16/32</td><td>Biolegend&amp;nbsp;</td><td>101301</td><td>AB_312800 (BioLegend Cat. No. 101301)</td></tr><tr><td>Trypan Blue&amp;nbsp;</td><td>Sigma-Aldrich&amp;nbsp;</td><td>T6146</td><td></td></tr><tr><td>Zombie NIR Fixable Viability Kit</td><td>Biolegend&amp;nbsp;</td><td>423105</td><td>viablity stain&amp;nbsp;</td></tr></tbody></table>

an advanced murine model for nonalcoholic steatohepatitis in association with type 2 diabetes

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Obesity is associated with chronic low-grade inflammation and insulin resistance, contributing to an increasing prevalence of chronic metabolic diseases, such as type 2 diabetes and nonalcoholic steatohepatitis (NASH). Recent research has established that pro-inflammatory immune cells infiltrate obese hypertrophic adipose tissue and liver. Given the emerging importance of immune cells in the context of metabolic homeostasis, there is a critical need to quantify and characterize their modification during the development of type 2 diabetes and NASH. However, animal models that induce pathophysiological features typical of human NASH are sparse.
In this article, we provide a detailed protocol to identify immune cell subsets isolated from liver and adipose tissue in a reliable mouse model of NASH, established by housing high-fat diet (HFD) mice under non-specific pathogen-free (SPF) conditions without a barrier for at least seven weeks. We demonstrate the handling of mice in non-SPF conditions, digestion of the tissues and identification of macrophages, natural killer (NK) cells, dendritic cells, B and T cell subsets by flow cytometry. Representative flow cytometry plots from SPF HFD mice and non-SPF mice are provided. To obtain reliable and interpretable data, the use of antibodies, accurate and precise methods for tissue digestion and proper gating in flow cytometry experiments are critical elements.
The intervention to restore physiological antigen exposure in mice by housing them in non-SPF conditions and unspecific exposure to microbial antigens could provide a relevant tool for investigating the link between immunological alterations, diet-induced obesity and related long term complications.

The protocol described allows the characterization of surface markers of innate and adaptive immune cells isolated from murine perigonadal adipose tissue and liver in a model of diet-induced NASH. In this model, NASH was induced by administration of HFD plus sucrose (6%) in drinking water for 7 to 15 weeks in C57Bl/6J mice, as previously reported13. Importantly, mice were housed in semi sterile conditions and, thus, exposed to environmental antigens throughout the experiment. HFD fed mice housed i...

A simple and reliable diet-induced rodent animal model for nonalcoholic steatohepatitis (NASH) is described, achieved through non-SPF housing of the animals and administration of a specific high-fat diet. We describe identification of hepatic and adipose immune cell subsets to recapitulate human immunological conditions by exposing mice to environmental germs.

Obesity is associated with chronic low-grade inflammation and insulin resistance, contributing to an increasing prevalence of chronic metabolic diseases, ...

an-advanced-murine-model-for-nonalcoholic-steatohepatitis-association

Research

JoVE Journal

Immunology and Infection

A protocol for chronic infusions of glucose and Intralipid in rats is described. This model can be used to study the impact of nutrient excess on organ function and physiological parameters.

A Model of Chronic Nutrient Infusion in the Rat

A preclinical, murine model of hepatic metastases performed via a hemispleen injection technique.

A Preclinical Murine Model of Hepatic Metastases

We present here a protocol for the isolation of islets from the mouse model of type 2 diabetes, Leprdb and details of a live-cell assay for measurement of insulin secretion from intact islets that utilizes 2 photon microscopy.

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

In this study, we describe a detailed protocol for inducing liver vesicular steatosis in differentiated HepaRG cells with the fatty acid salt sodium oleate and employ methods for detection and quantification of lipid accumulation, including coherent anti-Stokes Raman scattering (CARS) microscopy, cytofluorimetric analysis, Oil red O staining, and...

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

The present protocol optimizes the liver in situ perfusion/decellularization and two-photon microscopy methods to establish a reliable platform to visualize the dynamics of extracellular matrix (ECM) remodeling during non-alcoholic steatohepatitis (NASH).

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

This protocol presents a detailed approach to replicating a murine model of hyperlipidemia-induced heart failure with preserved ejection fraction (HFpEF). The design combines the administration of adeno-associated virus 9-cardiac troponin T-low-density lipoprotein receptor (AAV9-cTnT-LDLR) and poloxamer-407 (P-407).

A Murine Model of Hyperlipidemia&#45;Induced Heart Failure with Preserved Ejection Fraction

This protocol outlines a method for inducing diabetic cardiomyopathy through a combination of high-fat diet feeding and streptozotocin injection. This approach aims to provide a reliable framework for scientific investigation into diabetic cardiomyopathy and to explore potential avenues for clinical treatment applications.

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Mouse model of metabolic dysfunction-associated steatotic liver disease (MASLD) with metabolic dysfunction, hepatic gene expression changes, and liver histopathological alterations that resemble human MASLD, including fibrosis that progresses to advanced fibrosis stage 3. This model can be used in studies of MASLD pathophysiology and in pre-clinical studies of new therapies.

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

This study offers a reproducible and standardized method in order to establish obese rat models that exhibit simple obesity, commonly characterized by fatty pancreas. It also includes detailed protocols for pancreatic tissue sampling and immunohistochemistry.

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas

Trichuris muris infection is an intestinal model of Th2 immunity where resistant mice generate a protective Th2 response and susceptible mice generate a pathological Th1 response.

Trichuris muris Infection: A Model of Type 2 Immunity and Inflammation in the Gut

Learn to isolate adipose and hepatic immune cells from mice with diet-induced nonalcoholic steatohepatitis using non-SPF housing and flow cytometry. This method advances immunometabolism research.

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Explore More Videos